Tithi Biswas

List of Publications by Citations

Source: https://exaly.com/author-pdf/6737910/tithi-biswas-publications-by-citations.pdf

Version: 2024-04-28

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

546 13 59 21 h-index g-index citations papers 69 716 3.76 3.1 L-index avg, IF ext. citations ext. papers

#	Paper	IF	Citations
59	Complications from Stereotactic Body Radiotherapy for Lung Cancer. <i>Cancers</i> , 2015 , 7, 981-1004	6.6	60
58	Multi-Institutional Experience of Stereotactic Ablative Radiation Therapy for Stage I Small Cell Lung Cancer. <i>International Journal of Radiation Oncology Biology Physics</i> , 2017 , 97, 362-371	4	57
57	Tumor control probability modeling for stereotactic body radiation therapy of early-stage lung cancer using multiple bio-physical models. <i>Radiotherapy and Oncology</i> , 2017 , 122, 286-294	5.3	35
56	The survival benefit of neoadjuvant chemotherapy and pCR among patients with advanced stage triple negative breast cancer. <i>Oncotarget</i> , 2017 , 8, 112712-112719	3.3	29
55	Angiosarcoma of the breast: a rare clinicopathological entity. <i>American Journal of Clinical Oncology:</i> Cancer Clinical Trials, 2009 , 32, 582-6	2.7	28
54	Involved field radiation therapy following high dose chemotherapy and autologous stem cell transplant benefits local control and survival in refractory or recurrent Hodgkin lymphoma. <i>Radiotherapy and Oncology</i> , 2012 , 103, 367-72	5.3	26
53	Intensity-modulated radiation therapy and volumetric-modulated arc therapy for adult craniospinal irradiationa comparison with traditional techniques. <i>Medical Dosimetry</i> , 2013 , 38, 48-54	1.3	25
52	Primary pancreatic lymphoma: a population-based analysis using the SEER program. <i>American Journal of Clinical Oncology: Cancer Clinical Trials</i> , 2013 , 36, 38-43	2.7	23
51	Perioperative chemotherapy versus postoperative chemoradiotherapy in patients with resectable gastric/gastroesophageal junction adenocarcinomas: A survival analysis of 5058 patients. <i>Cancer</i> , 2017 , 123, 2909-2917	6.4	20
50	Evaluation of Definitive Stereotactic Body Radiotherapy and Outcomes in Adults With Extracranial Oligometastasis. <i>JAMA Network Open</i> , 2020 , 3, e2026312	10.4	17
49	Inflammatory TNBC Breast Cancer: Demography and Clinical Outcome in a Large Cohort of Patients With TNBC. <i>Clinical Breast Cancer</i> , 2016 , 16, 212-6	3	15
48	Prognostic potential of neutrophil-to-lymphocyte ratio and lymphocyte nadir in stage III non-small-cell lung cancer. <i>Future Oncology</i> , 2017 , 13, 1405-1414	3.6	15
47	Pathologic Complete Response (pCR) and Survival of Women with Inflammatory Breast Cancer (IBC): An Analysis Based on Biologic Subtypes and Demographic Characteristics. <i>International Journal of Environmental Research and Public Health</i> , 2019 , 16,	4.6	14
46	Emerging applications of stereotactic body radiotherapy. Future Oncology, 2014, 10, 1299-310	3.6	13
45	Controversies in the management of stage III non-small-cell lung cancer. <i>Expert Review of Anticancer Therapy</i> , 2014 , 14, 333-47	3.5	11
44	Race, insurance type, and stage of presentation among lung cancer patients. SpringerPlus, 2014, 3, 710		10
43	Oligometastases: history of a hypothesis. <i>Annals of Palliative Medicine</i> , 2021 , 10, 5923-5930	1.7	10

42	Local Control After Stereotactic Body Radiation Therapy for Stage I Non-Small Cell Lung Cancer. <i>International Journal of Radiation Oncology Biology Physics</i> , 2021 , 110, 160-171	4	10
41	Radiosensitization of non-small-cell lung cancer cells and xenografts by the interactive effects of pemetrexed and methoxyamine. <i>Radiotherapy and Oncology</i> , 2016 , 121, 335-341	5.3	9
40	Effect of Race and Insurance on the Outcome of Stage I Non-small Cell Lung Cancer. <i>Anticancer Research</i> , 2015 , 35, 4243-9	2.3	9
39	A multinational report of technical factors on stereotactic body radiotherapy for oligometastases. <i>Future Oncology</i> , 2017 , 13, 1081-1089	3.6	8
38	Local therapy for triple-negative breast cancer: a comprehensive review. Future Oncology, 2017, 13, 177	21 5. 673	0 8
37	Failure patterns and survival outcomes in triple negative breast cancer (TNBC): a 15 year comparison of 448 non-Hispanic black and white women. <i>SpringerPlus</i> , 2016 , 5, 756		8
36	Evaluating radiotherapy treatment delay using Failure Mode and Effects Analysis (FMEA). <i>Radiotherapy and Oncology</i> , 2019 , 137, 102-109	5.3	7
35	Using the Systemic Immune-Inflammation Index (SII) as a Mid-Treatment Marker for Survival among Patients with Stage-III Locally Advanced Non-Small Cell Lung Cancer (NSCLC). <i>International Journal of Environmental Research and Public Health</i> , 2020 , 17,	4.6	7
34	Low-dose radiosurgery for benign intracranial lesions. <i>American Journal of Clinical Oncology: Cancer Clinical Trials</i> , 2003 , 26, 325-31	2.7	7
33	Comparison of cisplatin/etoposide versus carboplatin/etoposide concurrent chemoradiation therapy for limited-stage small cell lung cancer (LS-SCLC) in the elderly population (age >65 years) using national SEER-Medicare data. <i>Practical Radiation Oncology</i> , 2016 , 6, e163-e169	2.8	7
32	The Association between Age, Comorbidities and Use of Radiotherapy in Women with Breast Cancer: Implications for Survival. <i>Medicines (Basel, Switzerland)</i> , 2018 , 5,	4.1	6
31	Primary squamous cell carcinoma of the prostate: a case report of a rare clinical entity. <i>Future Science OA</i> , 2015 , 1, FSO18	2.7	6
30	Modernizing Clinical Trial Eligibility Criteria: Recommendations of the ASCO-Friends of Cancer Research Prior Therapies Work Group. <i>Clinical Cancer Research</i> , 2021 , 27, 2408-2415	12.9	6
29	Evaluation of interfractional variation of organs and displacement of catheters during high-dose-rate interstitial brachytherapy for gynecologic malignancies. <i>Brachytherapy</i> , 2017 , 16, 1192-1	1798	5
28	Automated Quality Assurance of OAR Contouring for Lung Cancer Based on Segmentation With Deep Active Learning. <i>Frontiers in Oncology</i> , 2020 , 10, 986	5.3	5
27	The relation of race and type of health insurance to long-term risk of mortality among lung cancer patients in rural Eastern North Carolina. <i>North Carolina Medical Journal</i> , 2013 , 74, 464-9	0.6	5
26	Important prognostic factors for lung cancer in tobacco predominant Eastern North Carolina: study based on a single cancer registry. <i>Lung Cancer</i> , 2014 , 84, 116-20	5.9	4
25	Tumor localization accuracy for high-precision radiotherapy during active breath-hold. <i>Radiotherapy and Oncology</i> , 2019 , 137, 145-152	5.3	3

24	Late metastatic presentation is associated with improved survival and delayed wide-spread progression after ablative stereotactic body radiotherapy for oligometastasis. <i>Cancer Medicine</i> , 2021 , 10, 6189-6198	4.8	3
23	A simple matrix to predict treatment success and long-term survival among patients undergoing pancreatectomy. <i>Hpb</i> , 2019 , 21, 204-211	3.8	2
22	Chest wall and rib irradiation and toxicities of early-stage lung cancer patients treated with CyberKnife stereotactic body radiotherapy. <i>Future Oncology</i> , 2014 , 10, 2311-7	3.6	2
21	Patterns and Timing of Initial Relapse in Patients with Hodgkin and Non-Hodgkin Lymphoma <i>Blood</i> , 2006 , 108, 3673-3673	2.2	2
20	An analysis of a large multi-institutional database reveals important associations between treatment parameters and clinical outcomes for stereotactic body radiotherapy (SBRT) of oligometastatic colorectal cancer <i>Radiotherapy and Oncology</i> , 2021 ,	5.3	2
19	Diffuse Atypical Cystic Brain Metastases in ALK+ NSCLC Treated With Whole Brain Radiation and Second-Generation ALK-Targeted Therapy. <i>Practical Radiation Oncology</i> , 2019 , 9, e129-e133	2.8	1
18	Current topics in the multimodality treatment of locally advanced rectal cancer. <i>Future Oncology</i> , 2016 , 12, 963-79	3.6	1
17	Post-operative radiation therapy (PORT) in resected non-small cell lung cancer (NSCLC): An updated population based analysis <i>Journal of Clinical Oncology</i> , 2018 , 36, 8522-8522	2.2	1
16	Volumetric burden of metastatic lesions drives outcomes in patients with extracranial oligometastatic disease. <i>Cancer Medicine</i> , 2021 , 10, 8091-8099	4.8	1
15	The changing landscape of stage III lung cancer: a literature review. <i>Expert Review of Anticancer Therapy</i> , 2020 , 20, 675-686	3.5	1
14	Role of radiation in extensive stage small cell lung cancer: a National Cancer Database registry analysis. <i>Future Oncology</i> , 2021 , 17, 2713-2724	3.6	1
13	An international pooled analysis of SBRT outcomes to oligometastatic spine and non-spine bone metastases. <i>Radiotherapy and Oncology</i> , 2021 , 164, 98-103	5.3	1
12	Pretreatment neutrophil-to-lymphocyte ratio as an important prognostic marker in stage III locally advanced non-small cell lung cancer: confirmatory results from the PROCLAIM phase III clinical trial. <i>Journal of Thoracic Disease</i> , 2021 , 13, 5617-5626	2.6	0
11	Comparison of cisplatin- versus carboplatin-based concurrent chemoradiation for limited-stage small cell lung cancer using SEER-Medicare data <i>Journal of Clinical Oncology</i> , 2014 , 32, 7596-7596	2.2	O
10	40: Patterns of Failure in Extra-Cranial Oligometastatic Patients Treated with Definitive Stereotactic Body Radiotherapy (SBRT). <i>Radiotherapy and Oncology</i> , 2020 , 150, S20-S21	5.3	
9	Stereotactic body radiotherapy (SBRT) for T2N0 (>3 cm) non-small cell lung cancer: Outcomes and failure patterns. <i>Journal of Radiosurgery and SBRT</i> , 2021 , 7, 271-277	0.4	
8	Coordinated control of a 3DOF cartesian robot and a shape memory alloy-actuated flexible needle for surgical interventions: a non-model-based control method. <i>Robotica</i> ,1-18	2.1	
7	Involved Field Radiation Therapy Following Autologous Stem Cell Rescue for Hodgkin and Non-Hodgkin Lymphoma - Is It Efficacious? <i>Blood</i> , 2006 , 108, 3676-3676	2.2	_

LIST OF PUBLICATIONS

6	Demography and survival of inflammatory breast cancer (IBC) based on histological subtypes: A hospital-based registry analysis <i>Journal of Clinical Oncology</i> , 2018 , 36, e12587-e12587	2.2
5	An Integrated Framework Based on Full Monte Carlo Simulations for Double-Scattering Proton Therapy. <i>International Journal of Particle Therapy</i> , 2019 , 6, 31-41	1.5
4	A Modeling Approach to Radiation Therapy in the Era of COVID-19. <i>JAMA Network Open</i> , 2021 , 4, e213	8 50 .4
3	Analysis of patterns of care and benefit of thoracic radiotherapy for patients with stage IV NSCLC in the immunotherapy-era from a national hospital-based registry <i>Journal of Clinical Oncology</i> , 2021 , 39, 9123-9123	2.2
2	Prognostic value of SUVmax on FDG-PET/CT before and after stereotactic body radiotherapy (SBRT) on recurrence and survival in early-stage non-small cell lung cancer (NSCLC) <i>Journal of Clinical Oncology</i> , 2021 , 39, 8539-8539	2.2
1	Optimum treatment for mediastinal lymph node positive (N2) resectable non-small cell lung cancer: what is the role for surgery?. Expert Review of Anticancer Therapy, 2016 , 16, 1131-1144	3.5